TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.

Jacobus Pfisterer et al.PubMed ↗Publisher ↗

No numbers read from the abstract.